glp-1 drugs competitive intelligence 2025 Chart: 1 in 8 Americans Now Use for Weight Loss GLP-1 Agonists Market Report 2025-2033,
Description
While emerging data hint that GLP-1 therapies may offer added benefits, the evidence remains preliminary, and careful interpretation is essential
An article published in the New York Times in 2006 notes how people who had long struggled with type 2 diabetes had renewed faith in their ability to manage symptomsboth their blood sugar and their weightthanks to Byetta
Major cities like Mumbai, Delhi, and Bengaluru dominate the GLP-1 receptor agonist market due to their extensive healthcare infrastructure and the presence of leading pharmaceutical companies
For example, Wang et al
